Pharmaceutical
ViCardia Therapeutics, Inc., a Delaware corporation, founded in 2017, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for treating heart failure (HF) involving mitochondrial dysfunction.